Clinical Trials Sponsored by Centene Corporation

Total 69567 results

Celgene Corporation

Completed

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Celgene Corporation

Completed

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Multiple Myeloma

United States
Celgene Corporation

Completed

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Neoplasms | Metastases, Neoplasm

United States
Celgene Corporation

Completed

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene Corporation

Terminated

Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice (AMBER)

Breast Neoplasms

Spain
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
Celgene Corporation

Completed

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Germany
Celgene Corporation

Completed

Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer

Breast Cancer

United States
Celgene Corporation

Completed

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Crohn's Disease

France, United States, United Kingdom, Israel
Celgene Corporation

Completed

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Pharmacokinetics

United States
Celgene Corporation

Completed

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Newly Diagnosed Multiple Myeloma

Spain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
Celgene Corporation

Completed

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Celgene Corporation

Completed

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Cangene Corporation

Completed

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Liver Transplantation | Hepatitis B

United States, Canada
Cangene Corporation

Approved for marketing

Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection

Varicella
Celgene Corporation

Completed

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Boston Medical Center
Celgene Corporation

Completed

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

AL Amyloidosis

United States
Samsung Medical Center
Celgene Corporation

Completed

A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma (Ro-ENKTL)

Histologically Proven Extranodal NKTcell Lymphoma

Korea, Republic of
Tufts Medical Center
Celgene Corporation

Completed

Study of Apremilast in Atopic or Contact Dermatitis

Atopic Dermatitis | Allergic Contact Dermatitis

United States
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Celgene
Celgene Corporation

Terminated

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors

United States
Celgene
Celgene Corporation

Completed

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States, Australia
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Celgene Corporation

Terminated

Prevention of Restenosis Following Revascularization

Vascular Disease, Peripheral

United States
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Celgene Corporation

Completed

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) (CRPS)

Complex Regional Pain Syndrome (RSD)

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
Celgene
Celgene Corporation

Completed

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Lymphoma | Cancer

United States, United Kingdom
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
Celgene Corporation

Completed

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

United States
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Celgene Corporation

Completed

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Ireland, Spain, Australia, Austria, United Kingdom
Celgene Corporation

Completed

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Small Cell Lung Cancer

United States
Celgene Corporation

Withdrawn

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Celgene Corporation

Completed

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Neoplasms | Fatigue

United States
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene
Celgene Corporation

Completed

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell Lymphoma

United States, France, Germany, Poland, Russian Federation, United Kingdom
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Celgene Corporation

Withdrawn

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Metastatic Melanoma
Celgene Corporation

Terminated

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-002)

Complex Regional Pain Syndrome, Type I

United States
Celgene Corporation

Unknown

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders (HPDSC)

Hematologic Malignancies

United States
Celgene Corporation

Completed

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (SNAPIST-III)

Coronary Restenosis
Celgene Corporation

Completed

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Radiculopathy

United States
Celgene Corporation

Completed

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States

3

Subscribe